Search: onr:"swepub:oai:lup.lub.lu.se:aa591cac-8d16-423a-acde-f358ef76466b" > Pancreatic cancer -...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03833naa a2200313 4500 | |
001 | oai:lup.lub.lu.se:aa591cac-8d16-423a-acde-f358ef76466b | |
003 | SwePub | |
008 | 160401s2013 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/33471472 URI |
024 | 7 | a https://doi.org/10.3109/0284186X.2012.7441402 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Ansari, Danielu Lund University,Lunds universitet,Kirurgi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Surgery (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)med-dar |
245 | 1 0 | a Pancreatic cancer - cost for overtreatment with gemcitabine. |
264 | 1 | c 2013 |
520 | a Gemcitabine has been the standard chemotherapeutic agent in pancreatic cancer. However, two-thirds of pancreatic tumors display low expression of human equilibrative nucleoside transporter 1 (hENT1), which mediates cellular entry of the drug, and do not respond to gemcitabine therapy. The objective was to determine the costs of gemcitabine overtreatment and the cost-effectiveness of hENT1 testing using a Swedish pancreatic cancer cohort. Material and methods. The study population included 87 patients that were diagnosed with pancreatic cancer during 2008-2010 at Skåne University Hospital, Lund. A detailed review of treatments, side effects and resource utilization was performed. The proportion of hENT1-low was estimated at two-thirds based on previous evaluations of tumor samples from the Radiation Therapy Oncology Group (RTOG) trial 9704, the German AIO Pancreatic Cancer Group (AIO-PK) trial 0104, the Low hENT1 and Adenocarcinoma of the Pancreas (LEAP) trial and the authors' own institution. The cost of the hENT1 test was estimated at €50-200. Results. Sixty patients received gemcitabine and the other 27 best supportive care. Drug administration and hospitalization were the main expenditures. Grade 3 and 4 toxicities occurred in 42%, the most common being neutropenia (18%). The hospital costs related to gemcitabine overtreatment amounted to €5358 per pancreatic cancer patient, corresponding to as much as one-third of the total treatment cost. The health economical costs amounted to €9449 per patient when including indirect costs. Using hENT1 testing to select patients for gemcitabine therapy would save €8.6 million in Sweden each year. Conclusion. Total costs related to gemcitabine overtreatment were high. Individualizing gemcitabine treatment is cost-saving and would reduce unnecessary treatment-related toxicity. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a Tingstedt, Bobbyu Lund University,Lunds universitet,Kirurgi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Surgery (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)kir-bti |
700 | 1 | a Andersson, Rolandu Lund University,Lunds universitet,Kirurgi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Surgery (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)kir-ran |
710 | 2 | a Kirurgi, Lundb Sektion V4 org |
773 | 0 | t Acta Oncologicag 52:6, s. 1146-1151q 52:6<1146-1151x 1651-226X |
856 | 4 | u http://www.ncbi.nlm.nih.gov/pubmed/23244671?dopt=Abstracty FULLTEXT |
856 | 4 | u http://dx.doi.org/10.3109/0284186X.2012.744140y FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/3347147 |
856 | 4 8 | u https://doi.org/10.3109/0284186X.2012.744140 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view